- Home
- REX vs ANAB Comparison
REX vs ANAB Comparison
Compare REX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | ANAB |
|---|---|---|
| Founded | 1980 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | REX | ANAB |
|---|---|---|
| Price | $43.94 | $56.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $71.67 |
| AVG Volume (30 Days) | 159.3K | ★ 465.0K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $650,487,000.00 | $234,603,000.00 |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | N/A | $52.14 |
| P/E Ratio | $76.79 | ★ N/A |
| Revenue Growth | 1.24 | ★ 157.01 |
| 52 Week Low | $30.02 | $17.11 |
| 52 Week High | $64.95 | $73.30 |
Technical Indicators
Market Signals| Indicator | REX | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 48.33 |
| Support Level | $31.24 | $53.46 |
| Resistance Level | $49.85 | $57.70 |
| Average True Range (ATR) | 2.21 | 2.50 |
| MACD | -0.63 | 0.20 |
| Stochastic Oscillator | 15.22 | 60.25 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).